www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2538

Title: Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial
Authors: Van Vlierberghe, H
Leroux-Roels, G
Adler, M.
Bourgeois, N
Horsmans, Y
Brouwer, J
Colle, I
Delwaide, J
Brenard, R
Bastens, B.
Henrion, J
de Vries, RA
de Galocsy, C
Michielsen, P
Nevens, Y.
ROBAEYS, Geert
BRUCKERS, Liesbeth
Issue Date: 2003
Publisher: BLACKWELL PUBLISHING LTD
Citation: JOURNAL OF VIRAL HEPATITIS, 10(6). p. 460-466
Abstract: The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy with interferon alpha and ribavirin. Induction treatment could result in a faster early decline of the hepatitis C virus (HCV) load and a better response rate. Naive chronically infected HCV patients (n = 454) were randomized into two arms to receive either induction treatment with interferon alpha 2b 5 million units (MU) subcutaneously (s.c.) daily during a period of 8 weeks (arm A); or treatment with interferon alpha 2b 5 MU s.c. three times a week (TIW) for a period of 8 weeks (arm B). After week 8, interferon treatment in both arms was 3 MU s.c. TIW for a total period of 12 months. In both arms, ribavirin (1000-1200 mg orally per day) was added at week 4. Induction treatment resulted in a higher virological response at week 8 of treatment (66% vs 47'%; P < 0.01). However, response at the end of treatment and at 6 months follow-up was not different (53% vs 50%). 41%, vs 33%). The occurrence of adverse events and the drop-out rate were similar in both arms. Although an early virological response is observed more frequently in the induction treatment. end of treatment response and sustained responses did not differ.
Notes: State Univ Ghent Hosp, Dept Gastroenterol & Hepatol, B-9000 Ghent, Belgium. State Univ Ghent Hosp, Dept Clin Chem, B-9000 Ghent, Belgium. ULB Erasme, Dept Gastroenterol, Brussels, Belgium. KULeuven, Dept Hepatol, Louvain, Belgium. UCL, Dept Gastroenterol, Brussels, Belgium. Erasmus Univ, Hosp Dijkzigt, Dept Gastroenterol, NL-3015 GD Rotterdam, Netherlands. CHU Sart Tilman, Dept Gastroenterol, B-4000 Liege, Belgium. Clin St Joseph, Dept Gastroenterol, Liege, Belgium. Hop Jolimont, Dept Gastroenterol, Haine St Paul, Belgium. Rijnstate Hosp, Dept Gastroenterol, Arnhem, Netherlands. Clin St Anne St Remi St Etienne, Dept Gastroenterol, Brussels, Belgium. UZA, Dept Gastroenterol, Antwerp, Belgium. Acad Hosp St Jan, Dept Gastroenterol, Genk, Belgium. LUC Diepenbeek, Ctr Stat, Diepenbeek, Belgium.Van Vlierberghe, H, State Univ Ghent Hosp, Dept Gastroenterol & Hepatol, Pintelaan 185, B-9000 Ghent, Belgium.
URI: http://hdl.handle.net/1942/2538
DOI: 10.1046/j.1365-2893.2003.00466.x
ISI #: 000186323500010
ISSN: 1352-0504
Category: A1
Type: Journal Contribution
Validation: ecoom, 2004
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.